Displays the article's font size
Increase the font size for the article
Stocks of Tylenol maker Kamboo spiked before the opening bell the day after US President Donald Trump was promoted unproven promotions and, in some cases, advancing an unreliable bond between Tylenol, vaccines and autism.
“Don't take Tylenol,” Trump instructed pregnant women dozens of times at a White House press conference on Monday, and urged mothers not to give infants the commonly-named acetaminophen or the drug known in most other countries as paracetamol.
Shares of the New Jersey consumer brand company fell 7.5% on Monday. The stock reclaimed most of these losses in pre-market trading early Tuesday.
The presentation appeared to rely on existing research rather than important new research, but arrived as Director of Health and Human Services for vaccine skeptic Robert F. Kennedy Jr., to advance America's healthy moves focusing on what is seen as a potential cause of autism.
Kenvue disputed the relationship between drugs and autism this week, warning that if pregnant mothers do not use Tylenol when they are in need, they could suffer from fever or face dangerous choices while using a more risky alternative.
Trend now
Sikh activist targeted by India has been arrested on firearms charges
Dollarama stocks are rising rapidly. All costs may be the reason
Get weekly health news
Receive the latest medical news and health information provided every Sunday.
Kenvue was spin-off from Johnson & Johnson in 2023. With the exception of Tylenol, consumer health companies create band-aids, listerine and other household brand names.
City Investment Research Analyst Filippo Farolni believes the risks of new lawsuits after Trump's announcement are limited, but believes “there are risks to Tylenol consumption given the negative headlines.”
The company has filed hundreds of cases related to the product and allegedly linked to autism, but most have been dismissed.
Analysts expect a positive response to Kembo's stock at Opening Bell Tuesday, given the lack of new scientific evidence.
Shares of Summit, New Jersey-based Kenvue Inc. rose more than 7% in pre-market trading.
More Video Details
& Copy 2025 Canada Report